

1 **Impact of Synchronized Left Ventricular Pacing in Cardiac Resynchronization Therapy**

2 Yuichiro Miyazaki <sup>1, 2</sup>, Kohei Ishibashi <sup>\*1</sup>, Nobuhiko Ueda <sup>1</sup>, Satoshi Oka <sup>1, 2</sup>, Akinori  
3 Wakamiya <sup>1</sup>, Keiko Shimamoto <sup>1</sup>, Kenzaburo Nakajima <sup>1</sup>, Tsukasa Kamakura <sup>1</sup>, Mitsuru Wada <sup>1</sup>,  
4 <sup>2</sup>, Yuko Inoue <sup>1</sup>, Koji Miyamoto <sup>1</sup>, Satoshi Nagase <sup>1</sup>, Takeshi Aiba <sup>1</sup>, Kengo Kusano <sup>1,2</sup>

5

6 <sup>1</sup> Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita,  
7 Japan

8 <sup>2</sup> Department of Advanced Cardiovascular Medicine, Graduate School of Medical Sciences,  
9 Kumamoto University, Kumamoto, Japan

10 **Short title: Synchronized left ventricular pacing in CRT**

11 **\*Correspondence:**

12 Kohei Ishibashi, MD, PhD

13 Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 6-1

14 Kishibe-Shimmachi, Suita, Osaka 564-8565, Japan

15 Tel: +81-6-6170-1070

16 Fax: +81-6-6170-1348

17 E-mail: [kohei-ishibashi@ncvc.go.jp](mailto:kohei-ishibashi@ncvc.go.jp)

18

19 **Word count: 3528**

20 **Abstract**

21 **Background:** The adaptive cardiac resynchronization therapy (aCRT) algorithm enables  
22 synchronized left ventricular pacing (sLVP) to produce fusion with intrinsic right ventricular  
23 activation in normal atrioventricular (AV) conduction. Although sLVP presents benefits over  
24 biventricular pacing (BVP), the adequate sLVP rate for better clinical outcomes remains  
25 unclear. This study aimed to assess the association between sLVP rates and clinical outcomes.

26 **Methods:** Among our cohort of 271 consecutive patients who underwent CRT implantation  
27 between April 2016 and August 2021, we evaluated 63 patients who underwent CRT without  
28 considerably prolonged AV conduction and applied the aCRT algorithm (48 men, mean age: 64  
29  $\pm$  14 years; median follow-up period: 316 days [interquartile range: 212–809 days]).

30 **Results:** At the 6-month follow-up after CRT implantation, the frequency of CRT responders  
31 was 71% ( $n = 45$ ). The sLVP rate was significantly higher in responders than in non-responders  
32 ( $75 \pm 30$  vs.  $47 \pm 40$  %,  $p = 0.003$ ). Receiver operating characteristics (ROC) curve analysis  
33 revealed that the optimal cut-off value during the sLVP rate was 59.4% for prediction of CRT  
34 responders (area under the curve, 0.70; sensitivity, 80%; specificity, 61%; positive predictive  
35 value, 84%; and negative predictive value, 55%). Kaplan–Meier analysis demonstrated that the  
36 higher sLVP group (sLVP  $\geq 59.4\%$ ,  $n = 43$ ) had better prognosis (cardiac death and heart failure  
37 hospitalization) than the lower sLVP group (sLVP  $< 59.4\%$ ,  $n = 20$ ) (log-rank  $p < 0.001$ ), and  
38 multivariate Cox hazard analysis revealed that a higher sLVP rate was associated with good  
39 prognosis ( $p < 0.001$ ).

40 **Conclusion:** sLVP was associated with CRT response, and higher sLVP rate ( $\geq 59.4\%$ ) is  
41 important for good prognosis in patients with aCRT.

42

43 **KEYWORDS**

44 Adaptive CRT, cardiac resynchronization therapy, left ventricular pacing, responder

45

46 **CLINICAL PERSPECTIVE**

47 **What Is New?**

48 ▪ Synchronized left ventricular pacing(sLVP) >59.4% was a significant predictor of cardiac  
49 resynchronization therapy(CRT) responders and better clinical outcomes, evidenced by the  
50 results of the multivariate analysis.

51 ▪ In this study, which included patients with moderately prolonged PR intervals, high sLVP  
52 rates were associated with better clinical outcomes.

53 **What Are the Clinical Implications?**

54 ▪ sLVP rate was associated with the improvement of cardiac function after CRT implantation.

55 ▪ A higher sLVP rate was associated with a lower risk of cardiac death and heart failure  
56 hospitalization.

57

58 **LIST OF ABBREVIATIONS**

59 aCRT: Adaptive cardiac resynchronization therapy

60 AV: Atrioventricular

61 BVP: Biventricular pacing

62 ECG: Electrocardiogram

63 HF: Heart failure

64 ICM: Ischaemic cardiomyopathy

- 65 LBBB: Left bundle branch block
- 66 LVEF: Left ventricular ejection fraction
- 67 LVESV: Left ventricular end-systolic volume
- 68 NYHA: New York Heart Association
- 69 ROC: Receiver operating characteristics
- 70 SPECT: Single-photon emission computed tomography
- 71 sLVP: Synchronized left ventricular pacing
- 72 VV: Interventricular

## 73 1 INTRODUCTION

74 Cardiac resynchronization therapy (CRT) improves cardiac function and clinical outcomes in  
75 patients with symptomatic heart failure accompanied by decreased left ventricular ejection  
76 fraction (LVEF), QRS prolongation, and left bundle branch block (LBBB) (1). However, up to  
77 30% of patients do not see improvements in cardiac function and/or clinical prognosis after  
78 CRT implantation (2). The Adaptive CRT algorithm (aCRT) is a novel pacing algorithm for  
79 CRT that continuously optimises the atrioventricular (AV) and the interventricular (VV)  
80 delays based on heart rate and intrinsic AV conduction (3). In cases whereby the AV interval is  
81 shorter than 220 ms (during atrial sensing) or 270 ms (during atrial pacing), the aCRT  
82 algorithm uses the RV intrinsic conduction, which can provide synchronized left ventricular  
83 pacing (sLVP) to create fusion beat with the intrinsic conduction. In cases where the AV  
84 interval is extremely prolonged, the aCRT pacing provides biventricular pacing (BVP)  
85 without fusion with the intrinsic conduction. The sLVP was reported to have benefits over  
86 BVP regarding the risk of heart failure (HF), hospitalization, cardiac death, or atrial  
87 fibrillation (4,5). However, the adequate sLVP rate for better clinical outcomes remains  
88 unclear. This novel study aimed to assess the appropriate sLVP rate for recovering cardiac  
89 function in the mid-term, and to improve clinical outcomes in the long-term.

90

## 91 2 METHODS

### 92 2.1 Study population

93 This retrospective single-centre study included all consecutive patients who underwent CRT  
94 device implantation featuring the Adaptive CRT algorithm (Medtronic Inc., Minneapolis, MN,  
95 USA) (aCRT) between April 1, 2016, and August 31, 2021. The aCRT pacing mode was  
96 adapted just after the implantation. Patients who applied the pacing algorithm without adopting  
97 sLVP mode were excluded from this analysis. In addition, patients with persistent atrial

98 fibrillation, AV block, and extremely prolonged PR also were excluded from this analysis, due  
99 to difficulty in using sLVP.

100

101 This study was conducted in accordance with the principles outlined in the Declaration of  
102 Helsinki and approved by the ethics committee of our institution (M26-150-10). This is a  
103 retrospective study to analyze the anonymous data generated after patients have agreed to  
104 treatment; we applied the opt-out method to obtain informed consent.

105

## 106 **2.2 Study protocol**

107 The patients enrolled in this study were classified into two groups (CRT responder or  
108 non-responder) depending on the response to CRT pacing 6 months after CRT implantation.  
109 Next, we determined the required sLVP rate to become a CRT responder using a receiver  
110 operating characteristic (ROC) curve analysis. Thereafter, we compared the association  
111 between the sLVP rate and clinical prognosis.

112

## 113 **2.3 Cardiac examinations and definition of responses before and after CRT 114 implantation**

115 Cardiac systolic function was assessed using both echocardiography and single-photon  
116 emission computed tomography (SPECT) before and 6 months after CRT device implantation.  
117 Electrocardiogram (ECG)-gated myocardial perfusion SPECT imaging with technetium-99m  
118 (<sup>99m</sup>Tc) sestamibi was performed to measure cardiac systolic function and dimensions. All  
119 echocardiographic data were measured during three consecutive cardiac cycles. The left  
120 ventricular end-systolic volume (LVESV) and LVEF were measured using Simpson's biplane  
121 method.

122 CRT responders were described as patients with an improved LVEF >10% and/or reduced

123 LVESV >15% 6 months after CRT device implantation compared with baseline. Cardiac death  
124 and/or hospitalization for HF were evaluated as clinical outcomes. Cardiac death was defined  
125 as HF death, left ventricular assist device implantation, or death from ventricular arrhythmia.  
126 HF hospitalization was defined as a sudden or gradual onset of symptoms of New York Heart  
127 Association (NYHA) functional class III or IV HF, requiring unplanned hospitalization.

128

## 129 **2.4 Statistical analyses**

130 Data were analyzed using JMP software (version 11.2.01, SAS Institute, Cary, NC, USA).  
131 Continuous variables are presented as mean  $\pm$  standard deviation and were compared using  
132 Student's *t*-test. Categorical variables were compared using Fisher's exact test. The cumulative  
133 incidence and event-free curves were based on Kaplan–Meier analyses, stratified by study  
134 group, and contrasted using the log-rank test. Hazard ratios and odds ratios are reported with  
135 their 95% confidence intervals. To identify independent predictors of clinical response,  
136 univariable analyses were first performed, and predictors with a significance level <5%, age,  
137 and sex were included in the multivariable models. Multivariable analyses were performed  
138 using a Cox regression model. *P*-values of <0.05 were considered reflective of statistically  
139 significant differences.

140

## 141 **3 RESULTS**

### 142 **3.1 Patient characteristics**

143 Among our cohort of 271 consecutive patients who underwent CRT implantation between  
144 April 2016 and August 2021, we evaluated 63 patients who underwent CRT without  
145 considerably prolonged AV conduction on whom we applied the aCRT algorithm (48 men,  
146 mean age: 64  $\pm$  14 years) (Figure 1). The baseline characteristics of the patients are shown in  
147 Table 1. The number of patients with ischaemic cardiomyopathy (ICM) was 17 (27%), and

148 mean LVEF was  $23 \pm 7\%$ . Mean PR and QRS time were  $192 \pm 32$  ms and  $155 \pm 25$  ms,  
149 respectively, and the number of patients with LBBB was 31 (49%).

150

### 151 **3.2 CRT responder and synchronized left ventricular pacing rate**

152 At the 6-month follow-up after CRT implantation, the frequency of CRT responders was 71%  
153 ( $n = 45$ ) (Table 1). Patients with LBBB were significantly more frequent than those without.

154 There was no significant difference in the QRS width and rate of ICM. The sLVP rate was  
155 significantly higher in responders than in non-responders ( $75 \pm 30$  vs.  $47 \pm 40\%$ ,  $p = 0.003$ ).

156 ROC curve analysis revealed that the optimal cut-off value during sLVP rate was 59.4% for the  
157 prediction of CRT responders (area under the curve, 0.71; sensitivity, 80%; specificity, 61%;

158 positive predictive value, 84%; and negative predictive value, 55%) (Figure 2). Multivariate  
159 analysis showed that sLVP  $>59.4\%$  was an independent responder for CRT responder (odds

160 ratio: 4.52, 95% CI: 1.18–18.90,  $p = 0.027$ ) (Table 2).

161

### 162 **3.3 Clinical outcome of high sLVP rate**

163 During a median follow-up of 346 days (IQR, 223–760 days), one patient had cardiac death  
164 and 13 patients had HF hospitalizations. Five patients died during hospitalization because of

165 HF. Kaplan–Meier analysis demonstrated that the high sLVP group (sLVP  $\geq 59.4\%$ ,  $n = 43$ ) had  
166 a better prognosis (cardiac death and HF hospitalization) than the low sLVP group (sLVP

167  $<59.4\%$ ,  $n = 20$ ) (log-rank  $p < 0.001$ ) (Figure 3), and multivariate Cox hazard analysis revealed  
168 that higher sLVP rate was associated with good prognosis (hazard ratio: 0.10, 95% CI: 0.01–

169 0.40,  $p = 0.027$ ,  $p < 0.001$ ) (Table 3).

170

171



172 **4 DISCUSSION**

173 **Main findings**

174 The main findings of this study are as follows: (1) CRT responders had higher sLVP rates than  
175 CRT non-responders, (2) sLVP >59.4% was an excellent predictor of CRT response, and (3)  
176 sLVP >59.4% led to fewer cardiac deaths and hospitalizations due to HF.

177

178 **The mechanism of fusion beat of pacing and intrinsic conduction**

179 Recent CRT devices have the function to automatically adjust the fusion beat of self AV  
180 conduction and pacing. This regulatory function seems to lead to further narrowing of the QRS  
181 width after the CRT implantation (6). Previous studies have reported that the narrowing of QRS  
182 width after the CRT implantation can improve echocardiographic outcomes and long-term  
183 mortality (7,8). In addition to the function of adjusting the fusion beat, other studies have  
184 reported that sLVP could shorten QRS width compared with BVP (9,10). The sLPV may  
185 contribute to improved responder rate and better clinical outcomes by achieving QRS  
186 narrowing by creating the fusion beat with the intrinsic waveform and pacing.

187

188 **The adequate frequency of synchronized left ventricular pacing**

189 Adaptive CRT has an automatic adjustment algorithm for AV and interventricular delays based  
190 on frequent AV conduction evaluations. Furthermore, sLVP is often used for normal AV  
191 conduction (9). A previous study showed that sLVP provided better clinical outcomes than  
192 conventional BVP (4); however, the frequency of sLVP that leads to a better prognosis is not  
193 well known. Previous studies have defined the cut-off rate of sLVP to be 80% to predict clinical  
194 and echocardiographic parameters (9). Another study reported that an sLVP rate >50% was  
195 associated with better clinical outcomes compared with that of <50% (4). However, these rates  
196 are not statistically determined values. In this study, sLVP >59.4% was a significant predictor

197 of CRT responders and better clinical outcomes, evidenced by the results of the multivariate  
198 analysis. Using this criterion, we may be able to predict clinical responses, such as cardiac  
199 death and HF hospitalization.

200

### 201 **The association between synchronized left ventricular pacing and PR interval**

202 A previous study reported that LVP improved LV dp/dt max in patients with a PR interval <200  
203 ms (11). Other studies have also reported the effect of sLVP in patients with a normal PR  
204 interval (9,10); however, the significance of sLVP in patients with prolonged PR intervals is  
205 unknown. In this study, which included patients with moderately prolonged PR intervals, high  
206 sLVP rates were associated with better clinical outcomes. However, the patients with sLVP  
207 <59.4% had longer PR intervals than the patients with sLVP >59.4%. The sLVP rate appeared  
208 significantly affected by PR interval, especially in patients with prolonged PR intervals.  
209 Prolonged PR intervals are considered a significant factor in preventing a high sLVP rate. A  
210 previous report showed that RA septal pacing was associated with a shorter AV interval than  
211 right appendage pacing (12). The case report demonstrated that the sLVP rate was increased by  
212 RA septal pacing in patients with extremely prolonged PR intervals (424 ms). In this study,  
213 most patients experienced right appendage pacing. We should consider that the RA pacing lead  
214 is positioned at the RA septum in patients with a prolonged PR interval to increase the LPV  
215 rate.

216

## 217 **5 STUDY LIMITATIONS**

218 This study had some limitations. First, this was a retrospective single-centre study. The results  
219 of this study should be further confirmed by prospective and multi-centre studies in the future.  
220 Second, the sample size was small, which reduces the statistical strength of our findings. In  
221 order to resolve this point, it is necessary to collect cases in a multi-center study. Third, the

222 current study compared the mixture of sLVP and BVP. To clarify the effect of the sLVP, we  
223 have to compare the pure sLVP and the pure BVP.

224

## 225 **6 CONCLUSIONS**

226 Our study shows that the sLVP rate is associated with the CRT responder rate. A higher sLVP  
227 rate (>59.4 %) is associated with a lower risk of cardiac death and HF hospitalization.

228

229 **Data Availability:** The datasets generated and/or analyzed during the current study are  
230 available from the corresponding author upon reasonable request.

231

232 **Sources of Funding:** This research did not receive any specific grants from funding agencies  
233 in the public, commercial or not-for-profit sectors.

234

235 **Disclosures:** None.

236

237 **REFERENCES**

- 238 1. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ,  
239 Packer M, Clavell AL, Hayes DL, et al. Cardiac Resynchronization in Chronic  
240 Heart Failure. *New England Journal of Medicine*. 2002;346:1845–1853.
- 241 2. Pitzalis MV, Iacoviello M, Romito R, Massari F, Rizzon B, Luzzi G, Guida P,  
242 Andriani A, Mastropasqua F, Rizzon P. Cardiac Resynchronization Therapy  
243 Tailored by Echocardiographic Evaluation of Ventricular Asynchrony. *Journal of*  
244 *the American College of Cardiology*. 2002;40:1615–1622.
- 245 3. Martin DO, Lemke B, Birnie D, Krum H, Lee KL, Aonuma K, Gasparini M,  
246 Starling RC, Milasinovic G, Rogers T, et al. Investigation of a Novel Algorithm  
247 for Synchronized Left-Ventricular Pacing and Ambulatory Optimization of  
248 Cardiac Resynchronization Therapy: Results of the Adaptive CRT Trial. *Heart*  
249 *Rhythm*. 2012;9:1807–1814.
- 250 4. Birnie D, Lemke B, Aonuma K, Krum H, Lee KL, Gasparini M, Starling RC,  
251 Milasinovic G, Gorcsan J, Houmsse M *et al*. Clinical Outcomes with  
252 Synchronized Left Ventricular Pacing: Analysis of the Adaptive CRT Trial. *Heart*  
253 *Rhythm*. 2013;10:1368–1374.
- 254 5. Hsu JC, Birnie D, Stadler RW, Cerkenik J, Feld GK, Birgersdotter-Green U.  
255 Adaptive Cardiac Resynchronization Therapy Is Associated with Decreased Risk  
256 of Incident Atrial Fibrillation Compared to Standard Biventricular Pacing: A  
257 Real-World Analysis of 37,450 Patients Followed by Remote Monitoring. *Heart*  
258 *Rhythm*. 2019;16:983–989.
- 259 6. Thibault B, Ritter P, Bode K, Calò L, Mondésert B, Mangual JO, Badie N,  
260 McSpadden LC, Pappone C, Varma N. Dynamic Programming of Atrioventricular  
261 Delay Improves Electrical Synchrony in a Multicenter Cardiac Resynchronization

- 262 Therapy Study. *Heart Rhythm*. 2019;16:1047–1056.
- 263 7. Jastrzębski M, Baranchuk A, Fijorek K, Kisiel R, Kukla P, Sondej T, Czarnecka D.  
264 Cardiac Resynchronization Therapy-Induced Acute Shortening of QRS Duration  
265 Predicts Long-Term Mortality Only in Patients with Left Bundle Branch Block.  
266 *Europace*. 2019;21:281–289.
- 267 8. Hsing JM, Selzman KA, Leclercq C, Pires LA, McLaughlin MG, Mcrae SE,  
268 Peterson BJ, Zimetbaum PJ. Paced Left Ventricular QRS Width and ECG  
269 Parameters Predict Outcomes after Cardiac Resynchronization Therapy:  
270 PROSPECT-ECG Substudy. *Circulation. Arrhythmia and Electrophysiology*.  
271 2011;4:851–857.
- 272 9. Burns KV, Gage RM, Curtin AE, Gorcsan III J, Bank AJ. Left Ventricular-Only  
273 Pacing in Heart Failure Patients with Normal Atrioventricular Conduction  
274 Improves Global Function and Left Ventricular Regional Mechanics Compared  
275 with Biventricular Pacing: an Adaptive Cardiac Resynchronisation Therapy  
276 Sub-study. *European Journal of Heart Failure*. 2017;29:1335–1343.
- 277 10. Su Y, Hua W, Shen F, Zou J, Tang B, Chen K, Liang Y, He L, Zhou X, Zhang X, et  
278 al. Left Ventricular-Only Fusion Pacing versus Cardiac Resynchronization  
279 Therapy in Heart Failure Patients: A Randomized Controlled Trial. *Clinical  
280 Cardiology*. 2021;44:1225–1232.
- 281 11. Van Gelder BM, Bracke FA, Meijer A, Pijls NH. The Hemodynamic Effect of  
282 Intrinsic Conduction during Left Ventricular Pacing as Compared to Biventricular  
283 Pacing. *Journal of the American College of Cardiology*. 2005;46:2305–2310.
- 284 12. Murata Y, Ishibashi K, Yamagata K, Izumi C, Noguchi T, Kusano K. Impact of  
285 Atrial Septal Pacing in Left Ventricular-Only Pacing in Patients with a  
286 First-Degree Atrioventricular Block: A Case Series. *HeartRhythm Case Reports*.



288 **TABLES**

289

290 **Table 1. Baseline characteristics between responders and non-responders**

	All patients ( <i>n</i> = 63)	Responder ( <i>n</i> = 45)	Non-responder ( <i>n</i> = 18)	<i>P</i> -Value
Age, years	64 ± 14	65 ± 13	63 ± 15	<i>P</i> = 0.586
Men	48 (76%)	34 (76%)	14 (78%)	<i>P</i> > 0.999
Height, cm	166 ± 9	166 ± 9	166 ± 9	<i>P</i> = 0.984
Body weight, kg	61 ± 13	63 ± 12	57 ± 14	<i>P</i> = 0.093
CRT-D/CRT-P	56/7	38/7	18/0	<i>P</i> = 0.177
Secondary prevention	10 (16%)	5 (11%)	5 (28%)	<i>P</i> = 0.132
NYHA, II/III/IV	44(70%)/15(24%)/4(6%)	32(71%)/11(24%)/2(4%)	12(67%)/4(22%)/2(11%)	<i>P</i> = 0.617
ICM	17 (27%)	9 (20%)	8 (44%)	<i>P</i> = 0.063
HT	23 (37%)	19 (42%)	4 (22%)	<i>P</i> = 0.159
DM	18 (29%)	15 (33%)	3 (17%)	<i>P</i> =

				0.230
CKD	31 (49%)	21 (47%)	10 (56%)	<i>P</i> = 0.585
LVEF, %	23 ± 7	22 ± 7	24 ± 8	<i>P</i> = 0.386
LVESV, mL	181 ± 80	178 ± 84	190 ± 70	<i>P</i> = 0.630
PR time, ms	192 ± 32	188 ± 31	204 ± 34	<i>P</i> = 0.084
QRS time, ms	155 ± 25	159 ± 27	146 ± 18	<i>P</i> = 0.057
LBBB	31 (49%)	27 (60%)	4 (22%)	<i>P</i> = 0.011
LV only pacing, %	67 ± 35	75 ± 30	47 ± 40	<i>P</i> = 0.003
Cre, mg/dL	1.2 ± 0.6	1.2 ± 0.7	1.2 ± 0.4	<i>P</i> = 0.817
BNP, pg/mL	401 ± 473	352 ± 474	525 ± 459	<i>P</i> = 0.1913

291 Data are presented as the mean ± standard deviation or number (percentage).

292 Abbreviations: BNP, brain natriuretic peptide; CKD, chronic kidney disease; Cre, creatinine;

293 CRT-D, cardiac resynchronization therapy defibrillator; CRT-P, cardiac resynchronization

294 therapy pacemaker; DM, diabetes mellitus; HT, hypertension; ICM, ischaemic

295 cardiomyopathy; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction;

296 LVESV, left ventricular end-systolic volume; NICM, non-ischaemic cardiomyopathy; NYHA,



297 New York Heart Association.

298

299 **Table 2. Univariate and multivariate analyses for responder**

	Univariate analysis			Multivariate analysis		
	OR	95% CI	<i>P</i> -value	OR	95% CI	<i>P</i> -value
Age, 1 year increase	0.98	0.94–1.02	0.580	0.98	0.93–1.03	0.647
Men	0.88	0.21–3.09	0.850	0.65	0.12–2.92	0.589
ICM	0.31	0.09–1.02	0.054			
HT	2.55	0.77–10.13	0.126			
DM	2.50	0.68–11.99	0.170			
CKD	0.70	0.22–2.09	0.523			
LVEF, 1% increase	1.03	0.95–1.11	0.383			
LVESV, 1 mL increase	1.00	0.99–1.00	0.631			
PR, 1 ms increase	1.01	0.99–1.03	0.081			
QRS, 1 ms increase	0.97	0.95–1.00	0.051			
LBBB	5.25	1.59–20.91	0.005	2.81	0.68–12.76	0.149
sLVP>59.4%	6.28	1.95–21.91	0.001	4.52	1.18–18.90	0.027


300 Abbreviations: BNP, brain natriuretic peptide; CI, confidence interval; CKD, chronic kidney  
301 disease; DM, diabetes mellitus; HT, hypertension; ICM, ischaemic cardiomyopathy; LBBB,  
302 left bundle branch block; LVEF, left ventricular ejection fraction; LVESV, left ventricular  
303 end-systolic volume; OR, odds ratio; sLVP, synchronized left ventricular pacing.

304 **Table 3. Univariate and multivariate analyses for cardiac death and heart failure**  
 305 **hospitalization**

	Univariate analysis			Multivariate analysis		
	HR	95% CI	<i>P</i> -value	HR	95% CI	<i>P</i> -value
Age, 1 year increase	0.99	0.96–1.04	0.972	0.95	0.90–1.00	0.061
Men	0.68	0.22–2.53	0.541	0.63	0.15–2.88	0.541
ICM	2.51	0.82–7.32	0.102			
HT	0.28	0.04–1.03	0.055			
DM	1.00	0.27–3.04	0.999			
CKD	3.72	1.23–13.72	0.019	14.51	2.79–108.45	<0.001
LVEF, 1% increase	0.97	0.89–1.04	0.521			
LVESV, 1 mL increase	1.00	0.99–1.00	0.994			
PR, 1 ms increase	1.01	0.99–1.03	0.060			
QRS, 1 ms increase	0.98	0.96–1.00	0.149			
LBBB	0.26	0.05–0.84	0.023	0.41	0.08–1.55	0.198
sLVP>59.4%	0.12	0.02–0.40	<0.001	0.10	0.01–0.40	<0.001

306 Abbreviations: CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus;  
 307 HR, hazard ratio; HT, hypertension; ICM, ischaemic cardiomyopathy; LBBB, left bundle  
 308 branch block; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic  
 309 volume; sLVP, synchronized left ventricular pacing.

310 **FIGURES**




311

312 **Figure 1. Overview of the study population**

313 Among our cohort of 271 consecutive patients who underwent CRT implantation between  
314 April 2016 and August 2021, we evaluated 63 sLVP enabled CRT patients and applied the  
315 aCRT algorithm.

316 Abbreviations: AF, atrial fibrillation; AV, atrioventricular; CRT, cardiac resynchronization  
317 therapy; sLVP, synchronized left ventricular pacing.



318

319 **Figure 2. The association between CRT responder and synchronized left ventricular**  
320 **pacing rate**


321 Receiver operating characteristic curve analysis revealed that the optimal cut-off value during  
322 sLVP rate was 59.4% for the prediction of CRT responders.

323 Abbreviations: CRT, cardiac resynchronization therapy; sLVP, synchronized left ventricular  
324 pacing

325

326

327



328

329 **Figure 3** Kaplan–Meier analysis. The analysis demonstrates that the higher sLVP group  
330 (sLVP>59.4%, n = 43) had better prognosis (with regard to cardiac death and heart failure  
331 hospitalization) than the lower sLVP group (sLVP<59.4%, n = 20) (log-rank  $p<0.001$ ).

332 Abbreviations: sLVP, synchronized left ventricular pacing.